Marta Alegret
Overview
Explore the profile of Marta Alegret including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
1002
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Irisarri A, Corral A, Perez-Salvador N, Bellver-Sanchis A, Ribalta-Vilella M, Bentanachs R, et al.
Mol Med
. 2025 Feb;
31(1):73.
PMID: 39984825
This study investigated the effects of fat mass and obesity-associated (FTO) inhibition on cognitive function and metabolic parameters of senescence-accelerated mouse prone 8 (SAMP8) mice fed a high-fat diet (HFD)....
2.
Di Veroli B, Bentanachs R, Roglans N, Alegret M, Giona L, Profumo E, et al.
Cells
. 2024 Aug;
13(15.
PMID: 39120278
Sex differences may play a role in the etiopathogenesis and severity of metabolic dysfunction-associated steatotic liver disease (MASLD), a disorder characterized by excessive fat accumulation associated with increased inflammation and...
3.
Bentanachs R, Miro L, Sanchez R, Ramirez-Carrasco P, Amat C, Alegret M, et al.
Biomed Pharmacother
. 2024 Jun;
177:117067.
PMID: 38943989
Background And Aims: Drugs resolving steatotic liver disease (SLD) could prevent the evolution of metabolic dysfunction associated SLD (MASLD) to more aggressive forms but must show not only efficacy, but...
4.
Bentanachs R, Blanco L, Montesinos M, Sala-Vila A, Lazaro I, Rodriguez-Morato J, et al.
Nutrients
. 2023 Sep;
15(18).
PMID: 37764693
Non-alcoholic fatty liver disease is a sexual dimorphic disease, with adipose tissue playing an essential role. Our previous work showed that female rats fed a high-fat high-fructose diet devoid of...
5.
Roglans N, Laguna J, Alegret M
Curr Opin Lipidol
. 2023 Mar;
34(4):141-146.
PMID: 36942869
Purpose Of Review: Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent progressive condition that lacks a specific pharmacological treatment. ATP-citrate lyase (ACLY) is one of the emergent targets for...
6.
Roglans N, Fauste E, Bentanachs R, Velazquez A, Perez-Armas M, Donis C, et al.
Int J Mol Sci
. 2023 Jan;
24(1).
PMID: 36613916
We previously demonstrated that treatment with BemA (bempedoic acid), an inhibitor of ATP citrate lyase, significantly reduces fatty liver in a model of liver steatosis (HFHFr-female Sprague-Dawley rat fed a...
7.
Velazquez A, Bentanachs R, Sala-Vila A, Lazaro I, Rodriguez-Morato J, Sanchez R, et al.
Biomedicines
. 2022 Jul;
10(7).
PMID: 35884822
Bempedoic acid (BemA) is an ATP-citrate lyase (ACLY) inhibitor used to treat hypercholesterolemia. We studied the anti-steatotic effect of BemA, and the mechanisms involved, in a model of fatty liver...
8.
Velazquez A, Bentanachs R, Sala-Vila A, Lazaro I, Rodriguez-Morato J, Sanchez R, et al.
Mol Nutr Food Res
. 2022 Feb;
66(7):e2101115.
PMID: 35124887
Scope: The aim of this study is to delineate the contribution of dietary saturated fatty acids (FA) versus liquid fructose to fatty liver and hypertriglyceridemia. Methods And Results: Three groups...
9.
Bentanachs R, Velazquez A, Sanchez R, Alegret M, Laguna J, Roglans N
Clin Investig Arterioscler
. 2021 Dec;
34(2):57-67.
PMID: 34887111
Introduction: In its initial stages, nonalcoholic fatty liver disease presents hypertriglyceridemia and accumulation of lipids in the liver (hepatic steatosis). Bempedoic acid is an ATP:citrate lyase inhibitor that promotes a...
10.
Roglans N, Baena M, Sanguesa G, Velazquez A, Grinan-Ferre C, Pallas M, et al.
Food Nutr Res
. 2021 Oct;
65.
PMID: 34650394
Background: Non-alcoholic fatty liver disease (NAFLD) has increased over the last decades and may evolve into hepatocellular carcinoma (HCC). As HCC is challenging to treat, knowledge on the modifiable risk...